Treatment of sudden cardiac death: Current understandings from randomized trials and future research directions

Circulation

Volumn 95, Issue 12, 1997, Pages 2694-2699

  Domanski, Michael J ^a   Zipes, Douglas P ^b   Schron, Eleanor ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NONE

Author keywords

Arrhythmias; Cardiovascular disease; Death, sudden

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

CATHETER ABLATION; DEFIBRILLATOR; ENZYME INHIBITION; PRIORITY JOURNAL; REVIEW; SUDDEN DEATH; TREATMENT PLANNING;

EID: 0030906958     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.95.12.2694     Document Type: Review

References (42)

1. Myerburg R, Kessler KM, Castellanos A. Sudden cardiac death: epidemiology, transient risk, and intervention assessment. Ann Intern Med. 1993;119:1187-1197.
2. Myerburg R, Castellanos A. Cardiac arrest and sudden cardiac death. In: Braunwald E, ed. Heart Disease: A Textbook of Cardiovascular Medicine. Philadelphia, Pa: WB Saunders; 1996.
3. Mueller HS, Ayres SM. The role of propranolol in the treatment of acute myocardial infarction. Prog Cardiovasc Dis. 1977;19:405-412.
4. The MIAMI Trial Research Group. Metoprolol in acute myocardial infarction: arrhythmias. Am J Cardiol. 1985;56:35G-38G.
5. Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction, I: mortality results. JAMA. 1982;247:1707-1714.
6. Chadda K, Goldstein S, Byington R, Curb JD. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation. 1986;73:503-510.
7. The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med. 1981;304:801-807.
8. Teo K, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction: an overview of results from randomized controlled trials. JAMA. 1993;270:1589-1595.
9. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med. 1992;327:669-677.
10. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-1435.
11. The Studies of Left Ventricular Dysfunction Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med. 1991; 325:293-302.
12. Kober L, Torp-Pederson C, Carlsen JE, et al for The Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the ACE inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1995; 333: 1670-1676.
13. Ruberman W, Weinblatt E, Goldberg J. et al. Ventricular premature complexes and sudden death after myocardial infarction. Circulation. 1981:64:297-305.
14. Pratt CM. Theroux P. Slymen D, et al. Spontaneous variability of ventricular arrhythmias in patients at increased risk for sudden death after acute myocardial infarction: consecutive ambulatory electrocardiographic recordings of 88 patients. Am J Cardiol. 1987; 59:278-283.
15. Bigger JT, Fleiss JL, Kleiger R, et al. The relationships among ventricular arrhythmias, left ventricular dysfunction and mortality in the 2 years aller myocardial infarction. Circulation. 1984;69: 250-258.
16. Kennedy H, Whitlock J, Sprague M, et al. Long term follow-up of asymptomatic healthy subjects will frequent and complex ventricular ectopy. N. Engl J Med. 1985;312:193-197.
17. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainde and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-412.
18. The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Éngl J Med. 1992;327:227-233.
19. Siebels J, Cappato R, Ruppel R, Schneider MA, Kuck K, and the CASH Investigators. Preliminary results of the Cardiac Arrest Study Hamburg (CASH). Am J Candiol. 1993;72:109F-113F.
20. Waldo AL, Camm JA, de Ruyter H, Friedman PL, MacNeil DJ, Pitt B. Survival with oral d-sotalol in patients with left ventricular dysfunction after myocardial infarction: rationale, design, and methods (the SWORD Trial). J Am Coll Cardiol. 1995,75: 023-1027.
21. Mason JW for the Electrophysiologic Study Versus Electrocardiographic Monitoring Investigators. A comparison of electrophysiologic testing with Holter monitoring to predict antiarrhythmic drug efficacy for ventricular tachyarrhythmias. N Engl J Med. 1993; 329:445-451.
22. Burkart F, Pfisterer M, Kiowski W, Follath F, Burckhardt D. Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS). J Am Coll Cardiol 1990;16:1711-1718.
23. Ceremuzynski L, Kleczar K, Krzeminska-Pakula M, Kuch J. et al. Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo-controlled, pilot study. J Am Coll Cardiol. 1992;20:1056-1062.
24. Navarro-Lopez F, Cosin J, Marrugat J, Guindo J, de Luna A, for the SSSD Investigators. Comparison of the effects of amiodarone versus meteprolol on the frequency of ventricular arrhythmias and on mortality after acute myocardial infarction. Am J Cardiol. 1993; 72:1243-1248.
25. The CASCADE Investigators. Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE Study). Am J Cardiol. 1993;72:280-287.
26. Doval HC, Nul DL, Grancelli HO, Perrone SV, et al. Randomized trial of low-dose amiodarone in severe congestive heart failure. Lancet. 1994;344:493-498.
27. Singh S, Fletcher R, Fisher S, Singh B. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia: Survival Trial of Amiodarone in Patients with Congestive Heart-Failure. N Engl J Med. 1995;333:77-82.
28. Camm A, Julian D, Janse G, Munoz A, Schwartz P, Simon P, Frangin G, on behalf of the EMIAT Investigators: The European Myocardial Infarct Amiodarone Trial (EMIAT). Am J Cardiol. 1993;72:95F-98F.
29. Julian D, Camm A, Frangin G, Janse M, Schwartz P, Simon P, for the European Myocardial Infarct Amiodarone Trial Investigators. Randomized trial of effect of amiodarone on mortality in patients with left ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet. 1997;349:667-674.
30. Cairns JA, Connolly SJ, Roberts R, Gent M. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (CAMIAT): rationale and protocol. Am J Cardiol. 1993;72:87F-94F.
31. Cairns J, Connolly S, Roberts R, Gent M, for the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive premature depolarizations: CAMIAT. Lancet. 1997;349:675-682.
32. Mirowski M, Reid PK, Mower MM, Watkins L, et al. Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. N Engl J Med. 1980;303: 322-324.
33. Winkle RA, Mead RH, Ruder MA, Gaudiani V, et al. Long-term outcome with the automatic implantable cardioverter-defibrillator. J Am Coll Cardiol. 1989;13:1353-1361.
34. Zipes D, Roberts D. for the Pacemaker-Cardioverter-Defibrillator Investigators. Results of the international study of the implantable pacemaker cardioverter-defibrillator: a comparison of epicardial and endocardial lead systems. Circulation. 1995;92:59-65.
35. Moss A, Hall J, Cannom D, Daubert J, Higgins S, Klein H. Levine J, Sakseena S, Waldo A, Wilber D, Brown M, Moonseong H, for the Multicenter Automatic Defibrillator Implantation Trial. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med. 1996;335:1933-1940.
36. Friedman P, Stevenson W. Unsustained ventricular tachycardia: to treat or not to treat. N Engl J Med. 1996;335:1984-1985.
37. The AVID Investigators. Antiarrhythmics Versus Implantable Defibrillators (AVID): rationale, design, and methods. Am J Cardiol. 1995;75:470-475.
38. Connolly S, Gent M, Roberts R, Dorian P, et al. Canadian Implantable Defibrillator Study (CIDS): study design and organization. Am J Cardiol. 1993;72:103F-108F.
39. The CABG Patch Trial Investigators and Coordinators. The Coronary Artery Bypass Graft (CABG) Patch Trial. Prog Condiovasc Dis. 1993;36:97-114.
40. Buxton AE, Fisher JD, Josephson M, Lee K, et al. Prevention of sudden death in patients with coronary artery disease: the Multicenter Unsustained Tachycardia Trial (MUSTT). Prog Cardiovasc Dis. 1993;36:215-226.
41. Cupples L, Gagnon D. Kannel W. Long- and short-term risk of sudden cardiac death: population at risk. Circulation. 1992;85(suppl I):I-11-I-18.
42. Zipes DP. Sudden cardiac death: future approaches. Circulation. 1992;85(suppl I):I-160-I-166.